TD Cowen analyst Steve Scala reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $900.00. The ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,146.00. The company’s shares closed ...

This year's developments in the obesity market have really gone in Eli Lilly’s (NYSE:LLY) favor. Clinical trial results from competitors were largely underwhelming, including this week’s ...

Zepbound, as expected, was more effective in promoting weight loss. Eli Lilly's Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Eli Lilly, the world’s largest drugmaker by market value, is in advanced talks to buy cancer-focused ...

Investors with a lot of money to spend have taken a bullish stance on Eli Lilly LLY. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are ...

Eli Lilly's biggest catalyst at the moment comes from its hit weight loss medications, Mounjaro and Zepbound. Lilly is investing billions of dollars to scale manufacturing efforts as demand for ...

On Dec. 9, healthcare giant Eli Lilly announced the approval of a new $15 billion share buyback program and yet another significant dividend increase. For a seventh consecutive year, the company ...

Eli Lilly and Company will establish a new global capability centre in Hyderabad and recruit more than 1,000 highly skilled team members to strengthen its digital strategy and service delivery.

Eli Lilly (LLY) closed at $795.67 in the latest trading session, marking a -0.08% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 1.1%. Elsewhere ...